INSERM Unit 981

INSERM Unit 981
Name	INSERM Unit 981
Established	2005
Type	Research unit
City	Paris
Country	France
Parent	INSERM

INSERM Unit 981 is a biomedical research unit within the French Inserm network located in the Paris region, focusing on translational studies that connect basic science with clinical applications. The unit interacts with major institutions such as Université Paris Cité, École normale supérieure, Sorbonne Université, Hôpital Pitié-Salpêtrière, and Institut Pasteur, pursuing programs that bridge molecular biology, clinical trials, and public health initiatives. Its activities involve partnerships with organizations including CNRS, AP-HP, European Commission, Bill & Melinda Gates Foundation, and multinational corporations like Sanofi and Roche.

History

The unit was created in 2005 during a reorganization of French biomedical research that included contributions from INSERM, CNRS, Ministry of Higher Education and Research (France), Collège de France, and regional authorities such as the Île-de-France Regional Council. Early milestones involved collaborations with centers like Institut Curie, Hôpital Necker-Enfants Malades, Centre national de la recherche scientifique, and initiatives linked to programs funded by the European Research Council, ANR (Agence Nationale de la Recherche), and the FP7 framework. Over time the unit expanded through strategic links with clinical sites such as Hôpital Cochin, Hôpital Saint-Antoine, Institut Gustave Roussy, and research hubs including CEA, CNAM, and international nodes like Harvard Medical School, University of Oxford, and Karolinska Institutet.

Research Focus and Programs

Research at the unit spans molecular mechanisms, clinical investigation, and population studies with programs in areas connected to Alzheimer's disease, Parkinson's disease, HIV/AIDS, tuberculosis, and cancer immunotherapy. Ongoing projects draw on methodologies established by groups at Max Planck Society, Broad Institute, Wellcome Trust Sanger Institute, and Cold Spring Harbor Laboratory to implement genomics, proteomics, and bioinformatics pipelines inspired by work from Human Genome Project, 1000 Genomes Project, and ENCODE Project. Translational programs interface with clinical trial frameworks developed by European Medicines Agency, US Food and Drug Administration, and consortia like International Cancer Genome Consortium, Global Fund to Fight AIDS, Tuberculosis and Malaria, and WHO-led initiatives.

Organization and Staff

The unit's leadership structure echoes governance models used at INSERM, CNRS, Sorbonne Université, and Université Paris Cité, with a director supported by deputy directors, research team leaders, and administrative units similar to those at Institut Pasteur and Hôpital Européen Georges-Pompidou. Scientific staff include principal investigators with backgrounds from institutions such as Harvard University, Stanford University, University of California, San Francisco, Imperial College London, and ETH Zurich, alongside clinicians trained at Assistance Publique–Hôpitaux de Paris, Mayo Clinic, Johns Hopkins University, and Mount Sinai Health System. Technical personnel include bioinformaticians and technicians influenced by workflows from EMBL-EBI, Sanger Institute, and Broad Institute.

Collaborations and Partnerships

The unit maintains formal collaborations with academic partners like Université Paris-Saclay, École Polytechnique, Université de Strasbourg, and international partners including University of Cambridge, Yale University, Peking University, Max Planck Institutes, and National Institutes of Health. It participates in European consortia funded by Horizon 2020, bilateral agreements with agencies such as CNRS and German Research Foundation, and industry partnerships with corporations including Pfizer, AstraZeneca, Johnson & Johnson, and biotechnology firms modeled on ties seen at Institut Pasteur. Public–private initiatives reflect frameworks used by Innovative Medicines Initiative and philanthropic collaborations seen with Wellcome Trust and Gates Foundation.

Facilities and Resources

Facilities include wet laboratories, high-throughput sequencing centers, advanced imaging suites, and biobanks comparable to resources at Institut Pasteur, Institut Curie, CEA, and Institut Gustave Roussy. Core technologies incorporate platforms from vendors and centers associated with Illumina, Thermo Fisher Scientific, Zeiss, and computational clusters akin to those at CNRS and INRIA. Clinical research infrastructure aligns with trial units at AP-HP, data-management standards from EORTC, and biobanking protocols used by BBMRI-ERIC.

Notable Achievements and Publications

The unit has contributed to high-impact publications and collaborative reports in journals and outlets associated with Nature, Science, The Lancet, New England Journal of Medicine, and Cell, and to consortium datasets analogous to outputs from Human Cell Atlas and International Cancer Genome Consortium. Achievements include translational advances that cite methodological precedents from CRISPR-Cas9 studies at Broad Institute and EMBL, biomarker discoveries paralleling work at Memorial Sloan Kettering Cancer Center, and clinical protocols influenced by trials run at Mayo Clinic and MD Anderson Cancer Center. Its outputs have been presented at conferences such as American Society of Clinical Oncology, Society for Neuroscience, European Congress of Clinical Microbiology & Infectious Diseases, and Cold Spring Harbor Laboratory meetings.

Category:Research institutes in France